drugset / Trial / NCT06818474
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
NaSingle-groupOpen-labelTreatment
Summary
use of lanadelumab in patients with acquired angioedema
Timeline
- Start
- 2024-06-01
- Primary completion
- 2027-09-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanadelumab | Monoclonal antibody | 300 mg | — |